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Abstract
Background:  Liver fibrosis is a stage of non-alcoholic fatty liver disease (NAFLD) which is
responsible for liver-related morbidity and mortality in adults. Accordingly, the search for non-
invasive markers of liver fibrosis has been the subject of intensive efforts in adults with NAFLD.
Here, we developed a simple algorithm for the prediction of liver fibrosis in children with NAFLD
followed at a tertiary care center.
Methods: The study included 136 male and 67 female children with NAFLD aged 3.3 to 18.0 years;
141 (69%) of them had fibrosis at liver biopsy. On the basis of biological plausibility, readily
availability and evidence from adult studies, we evaluated the following potential predictors of liver
fibrosis at bootstrapped stepwise logistic regression: gender, age, body mass index, waist
circumference, alanine transaminase, aspartate transaminase, gamma-glutamyl-transferase, albumin,
prothrombin time, glucose, insulin, triglycerides and cholesterol. A final model was developed using
bootstrapped logistic regression with bias-correction. We used this model to develop the 'pediatric
NAFLD fibrosis index' (PNFI), which varies between 0 and 10.
Results: The final model was based on age, waist circumference and triglycerides and had a area
under the receiver operating characteristic curve of 0.85 (95% bootstrapped confidence interval
(CI) with bias correction 0.80 to 0.90) for the prediction of liver fibrosis. A PNFI ≥ 9 (positive
likelihood ratio = 28.6, 95% CI 4.0 to 201.0; positive predictive value = 98.5, 95% CI 91.8 to 100.0)
could be used to rule in liver fibrosis without performing liver biopsy.
Conclusion: PNFI may help clinicians to predict liver fibrosis in children with NAFLD, but external
validation is needed before it can be employed for this purpose.
Background
Pediatric non-alcoholic fatty liver disease (NAFLD) is a
highly prevalent and potentially serious complication of
childhood obesity [1]. NAFLD encompasses a spectrum of
disease from simple steatosis to non-alcoholic steatohep-
atitis (NASH), to fibrosis and ultimately cirrhosis [2].
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While simple steatosis has a benign prognosis, NASH and
fibrosis are responsible for liver-related morbidity and
mortality in adults [3-6].
Although the natural history of pediatric NAFLD is not
known, children with NAFLD followed at tertiary care
centers do often show some degree of fibrosis and less-fre-
quently frank cirrhosis [1,7]. The early identification of
fibrosis is especially important in children because it may
help to prevent the development of liver disease during
adulthood [1,8].
The diagnosis of liver fibrosis is based on liver biopsy
[2,9]. However, liver biopsy is invasive and limited by
hazard and discomfort to the patient [10]. Thus, there is a
recognized need for less-invasive strategies to identify the
minority of NAFLD patients with liver fibrosis [11,12].
These considerations are even more relevant for pediatric
age, where liver biopsy is generally perceived as bearing
greater risk and is less acceptable than in adults [13].
Several efforts have been made in recent years to identify
non-invasive markers of fibrosis in adults with NAFLD
[11,14]. Studies have focused on the use of clinical fea-
tures and routine laboratory exams or less readily availa-
ble serum markers of liver fibrosis [11,12,14,15].
However, all studies so far have been performed in adults
and there is a clear need to evaluate non-invasive
approaches in children [1].
The aim of the present study was to evaluate the ability of
selected clinical features and laboratory exams to predict
liver fibrosis in children with NAFLD using liver biopsy as
the gold standard. The choice of potential predictors was
made on the basis of biological plausibility, readily avail-
ability and evidence from adult studies [11,14].
Methods
Study design
We studied 203 children with NAFLD consecutively
admitted at the Liver Unit of the 'Bambino Gesù' Hospital
(Roma, Italy) between June 2004 and April 2008. NAFLD
was operationally defined as diffusely hyperechogenic
liver at ultrasonography with persistently elevated (i.e.
>40 U/L for at least 6 months) aspartate transaminase
(AST) or alanine transaminase (ALT) after exclusion of
viral, alcohol-induced, drug-induced, cholestatic and
genetic causes of liver disease [8]. The probability of a
child undergoing liver biopsy in this study reflected the
current practice at our center, which is based mostly on
the consensus of experts because of the scarcity of liver
biopsy data in children [1]. The study protocol conformed
to the Declaration of Helsinki and was approved by the
local ethical committee. Informed consent was obtained
from each patient or a responsible guardian.
Anthropometric assessment
Weight and height were measured using standard proce-
dures [16]. Waist circumference was measured at the high-
est point of the iliac crest [17,18]. Body mass index (BMI)
was calculated as weight (kg)/height (m)2. Standard devi-
ation scores (SDS) of weight, height and BMI were calcu-
lated from US reference data [19].
Laboratory assessment
ALT, AST, gamma-glutamyl-transferase (GGT), albumin,
prothrombin time (international normalized ratio
(INR)), glucose, triglycerides and cholesterol were evalu-
ated using standard laboratory methods. Insulin was
measured by radio-immuno-assay (Myria Technogenetics,
Milan, Italy). Glucose and insulin were measured at 0
(fasting), 30, 60, 90 and 120 minutes during an oral glu-
cose tolerance test (OGTT) performed with 1.75 g glucose
per kilogram of body weight (up to 75 g) [20]. The home-
ostasis model assessment index of insulin resistance
(HOMA-IR) and the insulin sensitivity index (ISI) were
calculated as surrogate markers of insulin sensitivity
[21,22].
Liver ultrasonography
Liver ultrasonography was performed by the same radiol-
ogist using a Siemens Sonoline Omnia instrument with a
5 MHz transducer (Siemens Medical Solutions, Mountain
View, CA, USA). Fatty liver was diagnosed according to
standard criteria [23,24].
Liver biopsy
Liver biopsy was performed using an automatic core
biopsy device (Biopince, Amedic, Sweden) equipped with
a 18-G needle. Only samples with length at least 15 mm
and including at least five portal tracts were considered.
Liver biopsies were routinely stained with hematoxylin-
eosin, Van Gieson, PAS-D and Prussian blue. The degree
of fibrosis was scored according to the Nonalcoholic Stea-
tohepatitis Clinical Research Network (0 = absence of
fibrosis; 1 = perisinusoidal or portal fibrosis; 2 = perisinu-
soidal and portal/periportal fibrosis; 3 = septal or bridging
fibrosis; 4 = cirrhosis) [9,18]. All liver biopsies were eval-
uated by the same pathologist who was blinded to the
ultrasonography and laboratory data.
Statistical analysis
Continuous variables are given as the median and inter-
quartile range (IQR) owing to skewed distributions. IQR
was calculated as the difference between the 75th and
25th percentile. Comparisons of continuous variables
between children with and without liver fibrosis were per-
formed with the Wilcoxon-Mann-Whitney test and those
of categorical variables with the Fisher's exact test. Spear-
man's rho was used to perform correlation analysis. The
outcome variable of prediction models was liver fibrosisBMC Medicine 2009, 7:21 http://www.biomedcentral.com/1741-7015/7/21
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of any degree (1 = yes; 0 = no). On the basis of biological
plausibility, readily availability and evidence from adult
studies [11,12,14,15], we evaluated the following series of
potential predictors: gender, age, BMI, waist circumfer-
ence, ALT, AST, GGT, albumin, INR, glucose, insulin, trig-
lycerides and cholesterol (Model 1). Owing to the pivotal
role of insulin resistance in the pathogenesis of NAFLD
[1,25,26], we also evaluated two models with HOMA-IR
(Model 2) or ISI (Model 3) in place of fasting glucose and
insulin. To identify candidate predictors of fibrosis, we
performed a stepwise logistic regression analysis on 1,000
bootstrap samples of 203 subjects (probability to enter =
0.05; probability to remove = 0.10) [27-29]. All variables
apart from gender were evaluated as continuous [30]. Lin-
earity of logits was ascertained using the Box-Tidwell pro-
cedure at preliminary univariable analysis. To linearize
logits, age, ALT, AST, insulin and triglycerides were trans-
formed using natural logarithms (loge). Multivariable
fractional polynomials were used to test whether the fit of
the multivariable models could be improved by transfor-
mation of continuous predictors [31]. As there was no
gain in fit, we left the predictors untransformed in the
final model. The 95% CIs of the regression coefficients of
the final model were calculated using 1,000 bootstrap
samples of 203 subjects with bias correction [32]. The
goodness of fit of the final model was checked using
standard diagnostic plots and the Hosmer-Lemeshow sta-
tistic [33]. The ability of the final model to discriminate
liver fibrosis was assessed by calculating the non-paramet-
ric area under the receiver-operating characteristic curve
(AUROC) with 95% CIs calculated on 1,000 bootstrap
samples with bias correction [34]. The probabilities
obtained from the final model were multiplied by 10 to
obtain the "pediatric NAFLD fibrosis index" (PNFI). The
true positive rate (TPR), true negative rate (TNR), positive
likelihood ratio (PLR), negative likelihood ratio (NLR),
positive predictive value (PPV) and negative predictive
value (NPV) of nine PNFI cut-points were calculated [27].
All statistical tests were two-tailed and statistical signifi-
cance was set to a p-value p < 0.05. Statistical analysis was
performed using STATA 10.1 (StataCorp, College Station,
Texas, USA).
Results
141 (69%) out of 203 children with NAFLD had liver
fibrosis. Most children had stage 1 (n = 115), a few had
stage 2 (n = 9) or 3 (n = 17), and none had stage 4 fibrosis.
Table 1 gives the measurements of the children with and
without liver fibrosis. Waist circumference (p < 0.0001),
GGT (p = 0.031), triglycerides (p < 0.0001) and choles-
terol (p < 0.0001) were higher in children with fibrosis
than in those without fibrosis while all of the other meas-
urements were similar.
Table 2 gives the bootstrap inclusion fraction, that is, the
number of times out of 1,000 that the candidate predic-
tors were selected at bootstrapped stepwise logistic regres-
sion in Models 1, 2 and 3. The variables selected most
frequently in all models were loge-transformed age
(100%), waist circumference (100%), and loge-trans-
formed triglycerides (≥ 99.9%). Expectedly, loge-trans-
formed age and waist circumference were strongly
correlated (Spearman's rho = 0.79, p < 0.0001). This is the
likely reason why age was selected as a predictor at boot-
strapped multivariable analysis despite the lack of signifi-
cance at univariable analysis.
The loge-transformed age, waist circumference and loge-
transformed triglycerides were thus entered into a boot-
strapped stepwise logistic regression model and probabil-
ities of liver fibrosis were computed. Table 3 gives the
coefficients of the final model with standard errors calcu-
lated by bootstrap analysis with bias correction. We mul-
tiplied the probabilities generated by this model per 10 to
obtain the PNFI. The PNFI can be calculated in two steps
as follows.
Table 1: Measurements of children with and without fibrosis.
Fibrosis
(n = 141)
No fibrosis
(n = 62)
p-value*
Gender (male/female) 96/45 40/22 0.630
Age (years) 12.1 (3.6) 11.6 (3.3) 0.807
Weight (kg) 62.0 (27.6) 58.9 (19.5) 0.378
Weight (SDS) 1.8 (1.1) 1.8 (1.3) 0.430
Height (m) 1.53 (0.23) 1.52 (0.15) 0.983
Height (SDS) 0.2 (1.4) 0.2 (2.1) 0.319
BMI (kg/m2) 26.4 (6.5) 25.4 (4.2) 0.078
BMI (SDS) 1.9 (0.7) 1.7 (0.6) 0.079
Waist circumference (cm) 94 (11) 87 (12) < 0.001
ALT (U/L) 67 (82) 66 (27) 0.414
AST (U/L) 47 (32) 42 (16) 0.070
GGT (U/L) 21 (19) 18 (11) 0.031
Albumin (mg/dl) 4.5 (0.4) 4.4 (0.6) 0.175
Prothrombin time (INR) 1.0 (0.2) 1.0 (0.3) 0.756
Glucose (mg/dl) 79 (11) 82 (11) 0.166
Insulin (μU/ml) 13 (10) 9 (7) 0.174
HOMA-IR 2.5 (2.1) 2.1 (1.7) 0.289
ISI 3.5 (3.0) 3.9 (2.6) 0.243
Triglycerides (mg/dl) 94 (58) 67 (39) < 0.001
Cholesterol (mg/dl) 166 (36) 145 (47) < 0.001
Continuous variables are given as median (interquartile range) and 
categorical variables as the number of subjects with the characteristic 
of interest. Abbreviations: SDS = standard deviation score; BMI = 
body mass index; ALT = alanine transaminase; AST = aspartate 
transaminase; GGT = gamma-glutamyl-transferase; INR = 
international normalized ratio; HOMA-IR = homeostasis model 
assessment index of insulin resistance; ISI = insulin sensitivity index.* 
Wilcoxon-Mann-Whitney test for continuous variables and Fisher's 
exact test for categorical variables.BMC Medicine 2009, 7:21 http://www.biomedcentral.com/1741-7015/7/21
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(1) Calculation of the linear predictor:
(2) Transformation of the linear predictor into the PNFI:
Diagnostic plots and the Hosmer-Lemeshow statistic (p =
0.251) showed adequate model fitting. The accuracy of
the prediction as detected by the AUROC was 0.85 (95%
bootstrapped CI with bias correction: 0.80 to 0.90).
Table 4 gives TPR, TNR, PLR, NLR, PPV and NPV for the
cut-points of PNFI. Values of PNFI = 9 could be confi-
dently used to rule in liver fibrosis (TNR = 98.4, PLR =
28.6 and PPV = 98.5). While the TPR (95.7%) of a PNFI
value less than three suggests that this cut-point may be
used to rule out liver fibrosis, the NPV (75.0%) is subop-
timal owing to the high pre-test probability of liver fibro-
sis in our series (69%).
Discussion
We developed and cross-validated the PNFI, a non-inva-
sive index for the prediction of liver fibrosis in children
with NAFLD. The PNFI, which is obtained from three very
simple measures (age, waist circumference and triglycer-
ides) could be used in place of liver biopsy to rule in liver
fibrosis in children with NAFLD followed at tertiary care
centers.
Waist circumference has been identified as an independ-
ent predictor of liver fibrosis in many studies of adults
with NAFLD [11,14]. We have recently shown that waist
circumference is a predictor of liver fibrosis independently
of the other components of the metabolic syndrome, BMI
and body fat [18]. Waist circumference is a surrogate
measure of visceral fat and may predict the development
of NAFLD in children [1,35]. A large waist circumference
is also an integral part of the definition of the metabolic
syndrome both in children as in adults [36,37]. Waist cir-
cumference in pediatric age must be interpreted taking age
into account [36-38]. Waist circumference and age were
strongly associated in our children and it was probably
because of this relationship that age was selected as a pre-
dictor of liver fibrosis at bootstrapped multivariable anal-
ysis.
Hypertriglyceridemia is a strong predictor of NAFLD in
the general population and in obese children [27,39,40].
Hypertriglyceridemia was also an independent predictor
of liver fibrosis in a study of obese adults [41]. The present
study shows that triglycerides are predictors of liver fibro-
sis in children with NAFLD and that their effect adds to
that of waist circumference. If this finding is confirmed in
further studies, liver fibrosis may be added to the meta-
bolic complications of the hypertriglyceridemic waist
phenotype [42]. In contrast to triglycerides and in agree-
ment with studies of NAFLD performed in the general
population [27], cholesterol was not a predictor of fibro-
sis.
Liver enzymes have not been uniformly found to predict
liver fibrosis in adults with NAFLD [14]. In the present
study, GGT but not ALT and AST were higher in children
with fibrosis. However, none of them was a predictor of
fibrosis at multivariable analysis. This confirms what is
already known from studies performed in adults, that is,
that liver enzymes are not reliable markers of NAFLD
severity as detected by liver biopsy [43].
lp =− × + × + × 6 539 0 207 1 957 .l o g [ ( ) ] . .l o g [ ee age years waist  (cm) tri iglycerides (mg/dl)] . −10 074
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+ − ×
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Table 2: Selection of candidate predictors at bootstrapped 
stepwise logistic regression.
Model 1 Model 2 Model 3
Male gender 243 241 253
Loge age 1,000 1,000 1,000
BMI 617 625 643
Waist 1,000 1,000 1,000
Loge ALT 378 362 350
Loge AST 281 325 341
GGT 389 363 357
Albumin 439 423 312
INR 189 226 208
Glucose 229 -- --
Loge insulin 286 -- --
HOMA-IR -- 218 --
ISI -- -- 300
Loge triglycerides 999 1,000 1,000
Cholesterol 233 198 161
The bootstrap inclusion fraction, i.e. the number of bootstrap samples 
out of 1,000 where the candidate predictors were selected, is given. 
Predictors selected for inclusion in the final model are marked in 
bold. Abbreviations: loge = natural logarithm; BMI = body mass index; 
ALT = alanine transaminase; AST = aspartate transaminase; GGT = 
gamma-glutamyl-transferase; INR = international normalized ratio; 
HOMA-IR = homeostasis model assessment index of insulin 
resistance; ISI = insulin sensitivity index.
Table 3: The prediction model of the pediatric non-alcoholic 
fatty liver disease fibrosis index
β 95% CI (β)* p-value
Loge age (years) -6.539 -9.358 to -4.137 < 0.001
Waist (cm) 0.207 0.135 to 0.286 < 0.001
Loge triglycerides (mg/dl) 1.957 1.009 to 3.018 < 0.001
Intercept -10.074 -15.838 to -5.028 < 0.001
Abbreviations: Loge = natural logarithm; β = regression coefficient; 
95%CI (β) = 95% confidence interval for the regression coefficient; p-
value = value of p for the regression coefficient. *Obtained on 1,000 
bootstrap samples of 203 subjects with bias-correction.BMC Medicine 2009, 7:21 http://www.biomedcentral.com/1741-7015/7/21
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Also albumin and prothrombin time did not contribute to
the prediction of liver fibrosis in our children. This was
not unexpected because these markers of liver function are
altered in patients with advanced liver disease while only
few of our children had advanced fibrosis.
Hyperinsulinemia is a common feature of pediatric
NAFLD and there is some evidence that it may be an inde-
pendent predictor of liver fibrosis [1,25]. In the present
study, however, insulin, HOMA-IR and ISI were not asso-
ciated with liver fibrosis. Even if ISI is a better marker of
insulin sensitivity as compared with fasting insulin and
HOMA-IR [44], this evidence had no practical implication
as far as the prediction of liver fibrosis is concerned.
Although this is the first study to investigate the possibil-
ity of a non-invasive diagnosis of liver fibrosis from clini-
cal and biochemical measurements in children with
NAFLD, it has some limitations. First, our series was
highly selected, being made of children followed at a ter-
tiary center specialized in pediatric liver disease. This lim-
itation is nonetheless common to all available scoring
systems for fibrosis because the decision to perform liver
biopsy is usually taken in tertiary centers and this is espe-
cially true for children [11,18]. This fact implies, however,
that our scoring system probably cannot be used in pri-
mary and secondary care because the 'case mix' and the
probability of liver fibrosis differ in these populations
[6,45,46]. Second, even if the internal cross-validation of
the scoring system was quite good according to current
standards, external cross-validation is needed before PNFI
can be used as predictor of liver fibrosis in clinical practice
or research [6,27,45,46]. Third, most of our children had
moderate fibrosis so that we could not develop a predictor
of severe fibrosis [15]. However, the prevalence and the
degree of fibrosis in our series strictly resemble those seen
in other pediatric series and there is some advantage in
detecting less-severe stages of fibrosis as the prevention of
chronic liver disease is concerned [1,11]. Fourth, at the
high prevalence rate of fibrosis observed in our series
(69%), PNFI could be used with confidence to rule in but
not to rule out fibrosis.
Conclusion
PNFI is a simple and non-invasive index based on age,
waist circumference and triglycerides that could be used in
place of liver biopsy to rule in liver fibrosis in children
with NAFLD followed at tertiary care centers. However,
before being employed for this purpose, PNFI must be
cross-validated in external populations.
Abbreviations
ALT: alanine transaminase; AST: aspartate transaminase;
BMI: body mass index; CI: confidence interval; GGT:
gamma-glutamyl-transferase; HOMA-IR: homeostasis
model assessment index of insulin resistance; INR: inter-
national normalized ratio (prothrombin time); ISI: insu-
lin sensitivity index; OGTT: oral glucose tolerance test;
NAFLD: non-alcoholic fatty liver disease; NASH: non-
alcoholic steatohepatitis; NLR: negative likelihood ratio;
NPV: negative predictive value; PLR: positive likelihood
ratio; PNFI: pediatric NAFLD fibrosis index; PPV: positive
predictive value; TNR: true negative rate; TPR: true posi-
tive rate.
Table 4: Diagnostic accuracy of the pediatric non-alcoholic fatty liver disease fibrosis index.
Cut-point n % TPR TNR PLR NLR PPV NPV
≥ 1 198 97.5 99.3
(96.1 to 100.0)
6.4
(1.8 to 15.7)
1.1
(1.0 to 1.1)
0.1
(0.01 to 1.0)
70.7
(63.8 to 76.9)
80.0
(28.4 to 99.5)
≥ 2 190 93.6 97.2
(92.9 to 99.2)
14.5
(6.9 to 25.8)
1.1
(1.0 to 1.3)
0.2
(0.1 to 0.6)
72.1
(65.2 to 78.4)
69.2
(38.6 to 90.9)
≥ 3 179 88.2 95.7
(91.0 to 98.4)
29.0
(18.2 to 41.9)
1.3
(1.1 to 1.6)
0.2
(0.1 to 0.3)
75.4
(68.4 to 81.5)
75.0
(53.3 to 90.2)
≥ 4 167 82.3 93.6
(88.2 to 97.0)
43.5
(31.0 to 56.7)
1.7
(1.3 to 2.1)
0.2
(0.1 to 0.3)
79.0
(72.1 to 84.9)
75.0
(57.8 to 87.9)
≥ 5 154 75.9 88.7
(82.2 to 93.4)
53.2
(40.1 to 66.0)
1.9
(1.4 to 2.5)
0.2
(0.1 to 0.4)
81.2
(74.1 to 87.0)
67.3
(52.5 to 80.1)
≥ 6 138 68.0 81.6
(74.2 to 87.6)
62.9
(49.7 to 74.8)
2.2
(1.6 to 3.1)
0.3
(0.2 to 0.4)
83.3
(76.0 to 89.1)
60.0
(47.1 to 72.0)
≥ 7 118 58.1 76.6
(68.7 to 83.3)
83.9
(72.3 to 92.0)
4.7
(2.7 to 8.4)
0.3
(0.2 to 0.4)
91.5
(85.0 to 95.9)
61.2
(50.0 to 71.6)
≥ 8 94 46.3 62.4
(53.9 to 70.4)
90.3
(80.1 to 96.4)
6.4
(3.0 to 13.9)
0.4
(0.3 to 0.5)
93.6
(86.6 to 97.6)
51.4
(41.6 to 61.1)
≥ 9 66 32.5 46.1
(37.7 to 54.7)
98.4
(91.3 to 100.0)
28.6
(4.0 to 201.0)
0.6
(0.5 to 0.6)
98.5
(91.8 to 100.0)
44.5
(36.0 to 53.3)
95% confidence intervals are given in parentheses. Abbreviations: TPR = true positive rate; TNR = true negative rate; PLR = positive likelihood 
ratio; NLR = negative likelihood ratio; PPV = positive predictive value; NPV = negative predictive value.BMC Medicine 2009, 7:21 http://www.biomedcentral.com/1741-7015/7/21
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